Zobrazeno 241 - 250
of 338
pro vyhledávání: ''
Publikováno v:
Molecular Cancer Therapeutics. 14:C65-C65
Background: Gene fusions involving members of the NTRK family have been identified in several types of cancer. The use of TRK inhibitors in vitro and in vivo have demonstrated activity against a number of different NTRK fusions in different tumor typ
Autor:
Yue Webster, Yung-mae M. Yao, Yong Gang Yue, Sheng-Bin Peng, Gregory P. Donoho, Philip W. Iversen, Henry James Robert, Gregory D. Plowman
Publikováno v:
Cancer Research. 75:LB-004
MAPK activation through KRas, NRas or BRaf mutation occurs in approximately 70% of colorectal cancer patients. Due to their epithelial origin, colorectal tumors generally have high levels of EGFR expression and activation. EGFR therapies such as cetu
Autor:
Mathew S. Varghese, Edward L. Chan, Michael J. Hayman, Anjaruwee S. Nimnual, Kristen A. VanHeyst, James Keller
Publikováno v:
Cancer Research. 75:3274-3274
Background: Epidermal Growth Factor Receptor (EGFR) is a biologic target for cancer therapy. Clinical response to EGFR inhibitors is variable. Recently, EGFR mutations were found to predict response to anti-EGFR therapy. Since a few children with Neu
Autor:
Clifford G. Tepper, Thomas J. Semrad, Irene M. Hutchins, Philip C. Mack, Stephenie Liu, Ryan R. Davis, Rebekah Tsai
Publikováno v:
Cancer Research. 75:5242-5242
Pancreatic cancer is a uniquely lethal malignancy characterized by frequent mutations in KRAS, CDKN2A, SMAD4, TP53 and many other genes. Molecular characterization is complicated by relatively few patients presenting with surgically resectable diseas
Autor:
Duroseau M, Jerome H. Check, Michael Dougherty, Jamie Vaniver, Gabrielle DiAntonio, Maya Srivastava
Publikováno v:
Cancer Research. 75:1282-1282
The BRCA genes normally provide proteins important in degradating the progesterone (P) receptor. BRCA1 and 2 mutations may make mutated protein, leading to prolongation of P receptor activity which may be involved in the mechanism of how these mutati
Publikováno v:
Cancer Research. 75:5473-5473
Gemcitabine (GEM) has shown clinical activity in several solid tumors such as pancreatic and biliary tract cancers, urinary cancer, and non-small cell lung cancers, but a substantial number of patients acquire GEM chemoresistance. GEM functions after
Autor:
Sally Bamford, Michael R. Stratton, Kenric Leung, Charlotte G. Cole, Mingming Jia, Prasad Gunasekaran, Dave Beare, Simon A. Forbes, Minjie Ding, Nidhi Bindal, Chai Yin Kok, Tisham De, Charambulos Boutselakis, Sari Ward, Peter J. Campbell, Jon W. Teague
Publikováno v:
Cancer Research. 75:62-62
COSMIC, the Catalogue Of Somatic Mutations In Cancer (http://cancer.sanger.ac.uk) is the world's largest and most comprehensive online resource for exploring the impact of somatic mutations in human cancer. Live since 2004, the 71st release (Nov 2014
Publikováno v:
Cancer Research. 75:4753-4753
Mutations on epidermal growth factor receptor (EGFR) cause a variety of cancers including breast and lung cancers. The single mutation T790M on tyrosine kinase domain of EGFR signifies the response to the popular cancer drug gefitinib, which leads to
Autor:
Patrick Tan, Byoung Chul Cho, Myung-Ju Ahn, Se-Hoon Lee, Tae-Min Kim, Huang Kie Kyon, Keon Uk Park, Hwan Jung Yun, Han Sang Kim
Publikováno v:
Cancer Research. 75:3949-3949
REV3L, a catalytic subunit of DNA polymerase zeta, is essential for tolerance of DNA damage via error-prone translesion synthesis. The goals of this study were to investigate the mutational landscape and predictive biomarkers of dacomitinib, Pan-ErbB
Autor:
Elizabeth M. Swisher, Kathy Q. Cai, Andrea J. Bernhardy, Yifan Wang, Neil Johnson, James S. Duncan, Maria I. Harrell, Emmanuelle Nicolas, Ryan M. Winters, Kelly E. Duncan
Publikováno v:
Cancer Research. 75:5467-5467
Introduction: Tumors harboring BRCA1 mutations initially respond well to platinum and PARP inhibitor therapy; however, resistance invariably arises and is a major clinical problem. The BRCA1 185delAG allele is a common founder mutation located close